What is Anoro Ellipta (umeclidinium/vilanterol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Anoro Ellipta?

Anoro Ellipta is a once-daily, fixed-dose combination inhaler containing umeclidinium 62.5 mcg (a long-acting muscarinic antagonist/LAMA) and vilanterol 25 mcg (a long-acting beta2-agonist/LABA) indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD). 1

Drug Composition and Delivery

Anoro Ellipta is delivered via the Ellipta dry powder inhaler device, which contains two separate foil blister strips—one with umeclidinium bromide and one with vilanterol trifenatate. 1 When activated, the device delivers approximately 55 mcg of umeclidinium and 22 mcg of vilanterol per inhalation. The lactose-based powder formulation contains milk proteins, which is relevant for patients with milk protein allergies. 1

Mechanism of Action

This dual bronchodilator works through complementary mechanisms:

  • Umeclidinium blocks muscarinic receptors in airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction
  • Vilanterol stimulates beta2-adrenergic receptors, causing direct bronchodilation and relaxation of airway smooth muscle

The combination provides additive bronchodilatory effects superior to either component alone. 1

Clinical Indications and Positioning

Anoro Ellipta is specifically indicated for maintenance treatment of airflow obstruction in COPD patients, including those with chronic bronchitis and/or emphysema. 1 According to the 2023 Canadian Thoracic Society guidelines, LAMA/LABA combinations like umeclidinium/vilanterol are recommended for patients with persistent moderate to severe dyspnea despite single bronchodilator therapy. 2

Critical Limitations

  • NOT indicated for relief of acute bronchospasm 1
  • NOT indicated for treatment of asthma 1
  • Should not be used as rescue medication

Clinical Efficacy

Umeclidinium/vilanterol demonstrates superior efficacy compared to:

  • Placebo and individual components (umeclidinium or vilanterol alone) 2
  • Once-daily tiotropium monotherapy 3
  • Twice-daily salmeterol/fluticasone combination 3

The combination improves multiple clinical outcomes including lung function (FEV1), dyspnea scores, rescue medication use, exacerbation rates, and health-related quality of life. 3, 4

Safety Profile

The medication is generally well-tolerated with:

  • Most common adverse events: headache and nasopharyngitis 3
  • No clinically relevant increased cardiovascular risk in pooled trial data 3
  • Overall adverse event incidence of approximately 28.8% in real-world Korean surveillance data 5
  • Serious adverse events occurring in approximately 5.9% of patients 5

Dosing Considerations

The standard dose is one inhalation once daily, with no adjustment needed for:

  • Geriatric patients 1
  • Patients with renal impairment (including severe CrCl <30 mL/min) 1
  • Patients with moderate hepatic impairment 1

Important Caveats

Patients with severely compromised lung function (FEV1 <30% predicted) can generate adequate inspiratory flow (mean 66.5 L/min) through the Ellipta device, though actual drug delivery depends on individual inspiratory flow profiles. 1

Practical Advantages

The once-daily dosing schedule and easy-to-use Ellipta inhaler device may improve medication adherence compared to multiple-times-daily regimens or more complex inhaler devices. 3, 6 This represents a significant practical advantage in COPD management where adherence is often suboptimal.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.